Ambu A/S AMBU-B.CO
Composite 53/100; the shares have moved about 40% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Balance-sheet strength ranks 84/100 — a strong point in its favour. Growth ranks 73/100 — a moderate point in its favour. Quality ranks 56/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Momentum ranks 28/100 — a moderate mark against it. Income ranks 38/100 — a slight mark against it.
What the company does Ambu A/S designs, manufactures, and markets single-use medical devices across endoscopy, neurology, cardiology, airway management, and emergency care. Its portfolio spans bronchoscopes, EEG electrodes, ECG leads, and training manikins, serving hospitals and clinics globally.
Key financials Ambu’s profitability metrics show mixed signals: ROE 8%, ROA 5%, and net margin 8% lag peers, while gross margin holds strong at 60%. Revenue growth is flat at 1% and EPS fell 35%, yet balance sheet strength is evident with debt/equity 0.09 and interest coverage 11x.
Stock health Momentum is weak: the stock is down 28% over 12 months and 35% from its 52-week high, with RSI at 64 (approaching overbought). Quality pillars are uneven—Strength scores 86 but Growth only 36 and Momentum 28, per Sideravia.
Price vs fair value The stock trades at a PREMIUM of 35.30% to our fair-value estimate of 46.68 and at a discount of 20.91% to the 12-month analyst target of 87.30. - Price trades at a forward P/E of 23x vs 39x trailing, suggesting growth expectations are embedded (Valuation 28.1 percentile). - Gross margin at 60% supports premium pricing power in single-use devices (Gross margin 60.0%). - Analysts (n=8) see 21% upside to 87.30, implying potential rerating if execution improves (Analyst 12-month target 87.30).
Looking forward Forward PEG of 0.33 implies undemanding valuation if growth resumes, but flat revenue and negative EPS momentum remain key risks. Execution on new product launches and margin recovery will likely drive the next rerating.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.